Polish biotech company Intelliseq, which focuses on automated analysis and interpretation of variations in the human genome, has successfully raised €4.5 million (PLN 19 million) in its latest funding round. This investment was led by Vinci HiTech, managed by Vinci S.A. with participation Unfold.vc and private investors, such as Tadeusz Wesołowski, the founder of Prosper S.A. The company shared the announcement with AIN in a press release.
About Intelliseq
-
Approximately 350 million people around the world are affected by rare genetic diseases, with many remaining undiagnosed for years due to the limitations of traditional lab methods. Founded in 2014 by scientists Klaudia Szklarczyk-Smolana, Marcin Piechota, Michał Korostyński, and Sławomir Gołda, Intelliseq develops bioinformatics tools that streamline automated DNA analysis and enhance genetic diagnostics.
-
The company partners strategically with various businesses and technology firms to provide solutions to research centers and laboratories globally. Its notable collaborations include the US-based Metrodora Institute, which specializes in diagnosing multi-system diseases, and DNAnexus, a digital platform supporting the UK Biobank, one of the largest genomic biobanks in the world.
-
Intelliseq, alongside the Metrodora Institute and its UK partner PrecisionLife, has created tools to evaluate predispositions to chronic fatigue syndrome and long COVID. By integrating with the DNAnexus ecosystem, Intelliseq offers advanced genomic analysis tools and reports on somatic cancers and hereditary diseases to prominent healthcare systems.
"Genomics is still only scratching the surface of its potential. Currently, it is mainly used for diagnosing complex cases and profiling cancer, but its applications go far beyond that. Emerging genomic data banks and advanced analytical algorithms pave the way for precision healthcare, personalized treatments, and better drug compatibility for patients. This is exactly where bioinformatics solutions are headed," says Klaudia Szklarczyk-Smolana, PhD, CEO of Intelliseq.
Deal details
-
The €4.3 million funding round was led by Vinci's investment fund. Vinci HiTech manages three different funds aimed at investing in Polish companies at various stages of their development.
-
The agreement also involved Unfold.vc and several private investors, including Tadeusz Wesołowski, who is a prominent figure in Poland’s pharmaceutical industry.
"Our priority is the continued commercialization and global deployment of advanced genome analysis tools. We see a growing demand for scalable bioinformatics solutions, especially in the U.S., where the molecular diagnostics market is expanding rapidly," says Klaudia Szklarczyk-Smolana, PhD, CEO of Intelliseq.
The fresh funds will propel the company’s entry into the US and advance the creation of cutting-edge algorithms for predicting disease risks. It will also drive Intelliseq’s potential to revolutionize diagnostics and personalized therapy globally.
